



## The effects of depression, stress, and somatization on clinical prognosis and treatment in patients suspicious of benign prostatic hyperplasia

Muhammad Sarim Khan , Muhammad Yawar Mushtaq, Usama Shoukat, Nauman Ahmed

Medical Officer, Shahabal Hospital Jhang

Medical Officer, Noshahi Surgical & Medicare hospital, Dera Bakha, Bahawalpur

Demonstrator of Pharmacology, Aziz Fatimah Medical and Dental College, Faisalabad

Lahore General Hospital Lahore

### ABSTRACT:

**Aim:** It was the first research to study how depression, stress, and somatoform disorder affect therapy reply for lower urinary tract symptoms (LUTS), suspicious of benign prostatic hyperplasia (BPH).

**Method:** Respondent Health Questionnaire-9, 7-item Sweeping Nervousness Syndrome Scale, and PHQ-17 are being used to assess LUTS/BPH individuals. The main result was just the responder's rate, which was defined as total IPSS score (6) at the conclusion of therapy.

**Results:** The intensity of LUTS/BPH was considerably greater in people experiencing sadness ( $p$  value = 0.025; storage sub-sign ( $p$  value = 0.023) or else somatization ( $p$  value = 0.026) than in these deprived of, although standard of living remained higher for cases experiencing anxiousness ( $p$  value = 0.039) than that of other deprived of. Nervous participants had a substantially larger number of non than those who were not (odds ratios [OR], 4.295,  $P$  = 0.023), whereas somatic respondents had the tendency to have greater non-responders (OR, 4.553,  $p$  value = 0.068). Our preliminary findings imply that sadness, anxiety, and somatic complaints might have had an impact on treatment manifestations of LUTS/BPH. Furthermore, apprehensive individuals with LUTS/BPH exhibited a worse response to therapy.

**Conclusion:** Despite its drawbacks, the current study shows that doctors may also need to conduct a detailed examination of psychotic features in order to successfully manage individuals suffering LUTS/BPH.

**Keywords:** Depression, stress, somatoform disorder, lower urinary tract signs prostatic hyperplasia.

### INTRODUCTION:

Lower urinary tract is frequent in elderly men and appear as a variety of medical signs just like storage, voiding, after postmicturition. Among the different etiologies and medical signs related through LUTS, benign prostatic hyperplasia is regarded the key factor and then also thoroughly matches their manifestations, albeit a definite association among LUTS and BPH is not entirely known [1]. The exact pathology of LUTS is presently unknown, it has now been regarded a perceptual sign of illness rather than a professional reliability and validity diagnoses. Including a major recent cross-sectional inhabitants'

## **The effects of depression, stress, and somatization on clinical prognosis and treatment in patients suspicious of benign prostatic hyperplasia**

investigation, negative impacts of LUTS appeared significant across numerous domains of QoL and comprehensive evaluations of physical medical status and mental wellbeing [2]. Furthermore, LUTS/BPH has a persistent, recurring, and challenging clinical course. As per a recent large catchment area research (n = 7,506) with the a 5-year follow-up for the evolutionary biology of LUTS, the incidence of LUTS rose from 21% at baseline to 23% at follow-up. Solitary slightly more than half (45%) of individuals through modest to simple LUTS at baseline dispatched or became slight LUTS at trail-up; the majority of males experiencing serious LUTS at baseline (63.6%) maintained to have serious LUTS at follow-up. Nevertheless, the therapy reaction to these drugs is insufficient [3].

According to a novel therapeutic recommendation, roughly 23 percent - 53 percent decrease in LUTS signs is typical afterwards medication with monotherapy of  $\alpha$ -receptor blockers and 5-reductase inhibition, depending on information from the multitude of brief-period also extended-term drug testing. Conversely, in certain investigations, medical manifestation of LUTS/BPH has been observed to be highly linked associated psychological abnormalities just like depression, anxiety, stress susceptibility, in addition impairment of fundamental tasks throughout daily [4]. Nevertheless, there seems to be a scarcity of scientific proof on the possible impact of such psychological abnormalities on clinical outcomes in individuals with LUTS/BPH up to this point. As a result, the goal of the current review remained to look into possible effects of depression, anxiousness, and somatization on procedure effects in cases through LUTS/BPH using brief, subscriber, in addition fast but affirmed rating scales, because timely also accurate assessment of alike psychiatric variables might very well help determine persons who are extra probable to gain from therapeutic approaches in everyday busy routine practice [5].

### **METHODOLOGY:**

Men aged 46 years were the primary following criteria, and a diagnostic testing of LUTS/BPH was determined by a health record, a thorough medical exam, and laboratory testing, counting prostate-specific antigen values. Because original study goals primarily observational studies, just a few exclusion criteria were used. Individuals with the physical signs, though, remained eliminated from the diagnosis stability study: 1) PSA level greater than 11 ng/mL, 2) the history of prostate cancer or scientific proof of prostate cancer through prostate biopsy, 3) preceding prostatic surgery, 4) slightly cause of LUTS other than BPH (i.e., neurogenic bladder, urinary contracture, urinary tract stricture, urinary malevolence, subacute vasculitis, or patients with long-lasting pyelonephritis), and 5) learning disability deficits and cognitive deficits. The major trial outcome was a responsiveness rate determined by the overall IPSS (8) score at the conclusion of therapy. The 6-point reaction threshold was adopted since an IPSS entire score of 8 indicated no or slight LUTS problems. Variations in over-all scores in addition 3 sub-scores on IPSS packing, constriction, and QoL subdomains from beginning to week 12 were secondary objectives. Other responder evaluations based on other parameters had included following: 1) 5 points and 2) 30% drop in IPSS total score from start to week 13 from premise to week 16. Concerning point drop with IPPS overall score in LUTS clinical studies, 5-to-7-point reduction was typical, and 5-point reduction were indicated to be the least for therapeutic outcome.

In terms of percent improvement of IPSS total score from baseline, decreases of 27 and 33 percent in IPSS overall score were the most commonly used. Unfortunately, neither the point decline nor the percent discount in IPSS entire score have been verified as usual reaction standards; instead, they have been experimentally employed by separate study groups. As a result, researchers experimentally selected a 5-point decline and a 33 percent decrease in IPSS over-all score as another feasible reply criterion.

**Statistical analysis:** The frequency of depression, anxiousness, and somatoform disorder was examined by means of student's t-test, the chi-square test without Yate's adjustment, or Fisher's test, by way of applicable. Changes in specific rating scales from beginning to week 18 have been examined using a chi -

# The effects of depression, stress, and somatization on clinical prognosis and treatment in patients suspicious of benign prostatic hyperplasia

squared test (ANOVA) that controlled for age, period of illness, and drug kind to investigate the effect of each diagnostic characteristic on multiple treatment results.

## RESULTS:

Ninety-three individuals took part in the trial. The average age of the overall population was 64 (62.89.1) years, and popular of patients remained married. Additional than half of the individuals had concomitant medical situations. The average overall IPSS score among all classes remained around 18, suggesting a reasonable degree of LUTS/BPH complaints. The average prostate volume (PV) and peak flow rate reached 37.9166.6 mL and 13.31.9 mL/sec, correspondingly; though, PV and  $Q_{\max}$  just weren't substantially differed by depression, stress, or somatoform disorder (Table 1). Furthermore, the PV and Qmax did not change substantially between responder and non-responders: 1) 34.317.3 mL vs. 39.416.9 mL and 14.62.5 mL/sec vs. 15.43.3 mL/sec, individually, by IPSS at endpoint (8); 2) 39.316.4 mL vs. 35.615.9 mL and 14.12.7 mL/sec vs. 15.64.2 mL/sec, including both, through IPSS reduction from background. Were there no disparities in demographic characteristics just like educational qualification, family past of LUTS/BPH, financial state, alcohol history, smoking history, otherwise marriage position. The overall LUTS/BPH score did not differ among two sets. Participants having anxiety had a substantially higher QoL sub-score (4.9 vs. 5.3,  $P=0.039$ ) than without. In the predictor variables analysis, nervous individuals had a substantially greater rate of non-response (OR, 4.295,  $P=0.023$ ) than these who were not (Tables 2, 3).

**Table 1:**

|                   | Somatization |           | Depression |           | Anxiety   |           |
|-------------------|--------------|-----------|------------|-----------|-----------|-----------|
|                   | Presence     | Absence   | Presence   | Absence   | Presence  | Absence   |
| Age               | 61.0±7.9     | 62.5±8.0  | 61.3±8.1   | 61.9±7.9  | 61.5±7.8  | 62.1±8.3  |
| Illness           | 15.0±14.3    | 16.9±11.7 | 14.7±17.8  | 11.9±10.6 | 13.4±14.3 | 13.9±16.7 |
| PV                | 34.6±15.6    | 40.0±14.9 | 36.1±15.7  | 38.0±15.3 | 35.1±14.3 | 38.6±16.6 |
| QMax              | 13.2±1.7     | 13.5±2.1  | 13.4±2.0   | 13.2±1.8  | 13.4±2.1  | 13.2±1.7  |
| <b>Medication</b> |              |           |            |           |           |           |
| Combination       | 19 (40.4)    | 18 (51.4) | 22 (47.8)  | 23 (39.7) | 17 (44.7) | 24 (43.6) |
| Ab only           | 16 (34.0)    | 18 (39.1) | 22 (37.9)  | 12 (34.3) | 19 (34.5) | 15 (39.5) |
| 5ARI only         | 12 (25.5)    | 6 (13.0)  | 13 (22.4)  | 5 (14.3)  | 12 (21.8) | 6 (15.8)  |
| <b>IPSS Total</b> |              |           |            |           |           |           |
| IPSS-QoL          | 14.7±7.6†    | 18.3±7.3  | 15.3±7.9*  | 18.±6.9   | 15.6±8.3  | 17.7±6.5  |
| PSS-Obs           | 8.9±5.3‡     | 11.0±4.8  | 9.4±5.4    | 10.9±4.5  | 9.5±5.4   | 10.7±4.6  |
| IPSS-Sto          | 5.8±3.6‡     | 7.3±3.5   | 5.8±3.7§   | 7.6±3.4   | 6.1±3.9   | 7.1±3.1   |

**Table 2:**

|          | Somatization |          | Depression |          | Anxiety  |          |
|----------|--------------|----------|------------|----------|----------|----------|
|          | IPSS Total   |          |            |          |          |          |
| IPSS-QoL | -2.4±4.2     | -3.0±3.7 | -2.6±4.0   | -2.9±3.9 | -2.9±4.1 | -2.3±3.7 |
| PSS-Obs  | -1.7±2.9     | -1.4±2.2 | -1.4±2.5   | -1.7±2.7 | -1.7±2.5 | -1.2±2.6 |
| IPSS-Sto | -1.0±1.5     | -0.8±1.2 | -0.7±1.3   | -1.1±1.3 | -0.9±1.4 | -0.9±1.2 |

## DISCUSSION:

Our initial findings indicate that sadness, anxiety, and somatoform disorder might indeed have an effect on patient manifestations of LUTS/BPH. Furthermore, apprehensive individuals with LUTS/BPH exhibited a

## The effects of depression, stress, and somatization on clinical prognosis and treatment in patients suspicious of benign prostatic hyperplasia

worse response to treatment [6]. The most significant important finding of this study is that it is the first to analyses the correlation of distress, somatic complaints, and nervousness to procedure activity in patients to LUTS/BPH, particularly through usage of simple, fast, dependable, well-authorized, also self-administered assessment scales that remain calm to manage also interpret including in busy routine practice [7]. The PV also Qmax, on the other hand, weren't really considerably different depending on the company or absenteeism of depression, anxiety, also somatization. It is possible that anxiety and urinary function share a same neurochemical foundation [8]. A convincing link seen among central besides peripheral serotonin and norepinephrine systems also lower urinary tract functions were presented repeatedly. In reality, duloxetine was licensed in Europe in 2008 for therapy of urinary incontinence. Furthermore, fluoxetine, a selective serotonin reuptake inhibitor, successfully restored urine regularity and detrusor overactivity induced by 5-HT deficiency [9]. In a recent study, differential relationships among psychiatric illnesses and LUTS were discovered in adult subjects, having melancholy being more linked through storage also post-micturition in male respondents. Similarly, current research reveals a link between storage symptoms and depression, lending credence to the prior conclusion that depressed individuals may well have higher urinary recurrence discomfort [10].

### CONCLUSION:

Considering challenges associated, the current investigation suggests that doctors may require comprehensive examination of melancholy, anxiety, and somatoform disorder disorders for the effective therapy of individuals with LUTS/BPH. Productivity and high with just a larger sample size and a great product might well be needed to test and maintain the new exploratory research outcomes.

### REFERENCES:

1. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. *Gastroenterology*. 2019; **150**(6): 1257- 1261.
2. Palsson OS, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. *Gastroenterology*. 2020; **158**(5): 1262- 1273.e1263.
3. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. *Gastroenterology*. 2019; **150**(6): 1262- 1279.
4. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. *Gastroenterology*. 2019; **150**(6): 1393- 1407.
5. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. *Gastroenterology*. 2019; **130**(5): 1480- 1491.
6. Choung RS, Locke GR III, Zinsmeister AR, Schleck CD, Talley NJ. Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule. *Am J Gastroenterol*. 2019; **104**(7): 1772- 1779.
7. Singh P, Lee HN, Rangan V, et al. Similarities in clinical and psychosocial characteristics of functional diarrhea and irritable bowel syndrome with diarrhea. *Clin Gastroenterol Hepatol*. 2020; **18**(2): 399- 405.e391.
8. Bai T, Xia J, Jiang Y, et al. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: a cross-sectional survey. *J Gastroenterol Hepatol*. 2017; **32**(5): 1018- 1025.
9. Vork L, Weerts Z, Mujagic Z, et al. Rome III vs Rome IV criteria for irritable bowel syndrome: a comparison of clinical characteristics in a large cohort study. *Neurogastroenterol Motil*. 2018; **30**(2):e13189
10. Aziz I, Törnblom H, Palsson OS, Whitehead WE, Simrén M. How the change in IBS criteria from Rome III to Rome IV impacts on clinical characteristics and key pathophysiological factors. *Am J Gastroenterol*. 2018; **113**(7): 1017- 1025.